Companies

Celanese Corp - Series A

NYSE: CE
$45.20
▼ $1.46 (−3.13%) today
Markets closed · 6:45pm ET

Q3 2025 Earnings

Reported Nov 6, 2025, 4:25pm ET · SEC source
$1.34
Beat +9.59%
EPS · est. $1.22
$2.4B
Miss −3.71%
Revenue · est. $2.5B
+2.3%
Beating market
CE vs S&P since report
1 quarter
Consecutive EPS beats

Market Reaction

% change · around the report
−10%−5%0+5%Nov 6Nov 7report 4:25pm ETearnings+0.1%+4.7%
−10%−5%0+5%Nov 6Nov 7earnings+0.1%+4.7%
CE +4.7%S&P 500 +0.1%
−10%−5%0+5%Nov 6Nov 7report 4:25pm ETearnings−0.3%+4.7%
−10%−5%0+5%Nov 6Nov 7earnings−0.3%+4.7%
CE +4.7%NASDAQ −0.3%
−5%0+5%Nov 5Nov 14report 4:25pm ETearnings+0.1%−0.2%
−5%0+5%Nov 5Nov 14earnings+0.1%−0.2%
CE −0.2%S&P 500 +0.1%
−5%0+5%Nov 5Nov 14report 4:25pm ETearnings−0.5%−0.2%
−5%0+5%Nov 5Nov 14earnings−0.5%−0.2%
CE −0.2%NASDAQ −0.5%
+14.37%
Day of report
−0.02%
Next session
−5.71%
One week
+4.75%
30 days

S&P 500 over the same 30 days: +2.47%.

Did CE Beat Earnings? Q3 2025 Results

Celanese delivered a mixed Q3 2025, posting adjusted EPS of $1.34 against a consensus estimate of $1.22, a beat of 9.59%, even as revenue of $2.42 billion fell short of the $2.51 billion analysts expected and declined 8.7% year-over-year amid persistent demand weakness across most end-markets. The headline GAAP results were dominated by $1.49 billion in non-cash asset impairment charges, including significant goodwill and trade name writedowns in the Engineered Materials segment, underscoring the difficult operating environment the specialty chemicals maker continues to navigate. A standout bright spot was free cash flow of $375 million, a sharp recovery from negative free cash flow in the year-ago period, fueled by cost reductions and inventory drawdowns. The company also signed a definitive agreement to divest its Micromax® portfolio for approximately $500 million, with proceeds earmarked for debt reduction. Looking ahead, management guided Q4 adjusted EPS to $0.85 to $1.00, reflecting typical western hemisphere seasonality, while targeting full-year 2025 free cash flow of $700 million to $800 million as deleveraging remains the central strategic priority.

Key Takeaways
  • Cost reduction programs targeting discretionary spend, SG&A, and logistics/distribution
  • Product mix enrichment through High Impact Programs (HIPs) emphasizing specialty offerings
  • Inventory reduction of approximately $100 million targeted in Engineered Materials for 2025
  • Production optimization at low-cost U.S. based assets with reduced operating rates at higher cost sites

“Our strong third quarter free cash flow and Micromax® divestiture announcement clearly demonstrate that we are executing against our strategic action plans. Our third quarter free cash flow performance is a substantial improvement over the same period last year and shows the robust cash generation capabilities we have and continue to utilize. The signing of the Micromax® divestiture demonstrates our commitment to aggressively and prudently taking steps to deleverage our balance sheet. I thank our teams for their tenacity and resilience in driving these outcomes.”

Celanese CEO, on the earnings call

Forward Guidance & Outlook

Celanese expects Q4 2025 volume declines due to western hemisphere seasonality, partially offset by continued cost reduction efforts. Q4 2025 adjusted EPS is guided to $0.85 to $1.00. Full-year 2025 free cash flow is expected in the range of $700 to $800 million. The company remains focused on generating cash to accelerate deleveraging, intensifying cost improvements, and driving top-line growth, with the Micromax® divestiture expected to close in Q1 2026 and proceeds directed to debt reduction.

CE YoY Financials

Q3 2025 vs Q3 2024 · SEC filings Q3 2024 Q3 2025
$0$800.0M$1.6B$2.4B$2.6B$2.4BRevenue$622.0M$521.0MGross Profit
$0$800.0M$1.6B$2.4BRevenueGross Profit

CE Revenue by Segment

Engineered Materials$1.4B
Acetyl Chain$1.1B

Figures from SEC filings and company reports. Not investment advice.